Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -100.05% is 77% above its 2-year average of -443.21%, near the high end of its 2-year range (-2152.52%–-70.44%).
44.48% above its 12-month average of -180.21%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -316.28%.
EBITDA MARGIN
-100.05%
EBITDA MARGIN AVG TTM
-180.21%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+44.48%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$244.74M
EBITDA Margin
-1441.45%
TTM Avg
-4661.83%
3Y Avg
-5918.79%
5Y Avg
-3944.51%
Market Cap
$234.18M
EBITDA Margin
25.65%
TTM Avg
38.25%
3Y Avg
43.91%
5Y Avg
51.79%
Market Cap
$237.64M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$241.94M
EBITDA Margin
6.37%
TTM Avg
-0.39%
3Y Avg
-2.45%
5Y Avg
1.13%
Market Cap
$239.35M
EBITDA Margin
-3813.88%
TTM Avg
-3607.01%
3Y Avg
-5701.50%
5Y Avg
-5701.50%
Market Cap
$242.28M
EBITDA Margin
32.18%
TTM Avg
32.18%
3Y Avg
-276.01%
5Y Avg
-1681.16%
Market Cap
$238.16M
EBITDA Margin
10.49%
TTM Avg
1.20%
3Y Avg
-4.19%
5Y Avg
-40.04%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $237.16M | -100.05% | -180.21% | N/A | N/A |
| High Tide Inc. (HITI)vs › | $238.57M | 1.66% | 3.74% | -1.53% | 0.81% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $244.74M | -1441.45% | -4661.83% | -5918.79% | -3944.51% |
| SIGA Technologies, Inc. (SIGA)vs › | $234.18M | 25.65% | 38.25% | 43.91% | 51.79% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $237.64M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | 6.37% | -0.39% | -2.45% | 1.13% |
| Quantum-Si incorporated (QSI)vs › | $239.35M | -3813.88% | -3607.01% | -5701.50% | -5701.50% |
| Q32 Bio Inc. (QTTB)vs › | $242.28M | 32.18% | 32.18% | -276.01% | -1681.16% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $238.16M | 10.49% | 1.20% | -4.19% | -40.04% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.43M | 37.26% | 38.63% | 43.69% | 46.28% |
Gross Margin
91.3%
EBITDA Margin
-100.0%
Operating Margin
-104.0%
Net Margin
-183.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -316.28% |
| 2026-03-31 | -310.12% |
| 2025-12-31 | -70.44% |
| 2025-09-30 | -80.68% |
| 2025-06-30 | -123.51% |
| 2025-03-31 | -143.17% |
| 2024-12-31 | -128.17% |
| 2024-09-30 | -664.00% |
| 2024-06-30 | -2152.52% |
